Related Experiment Video
Updated: Jun 22, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer
Kennady K Bullock1, Ann Richmond1
1Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, TN 37232, USA.
Abstract:
The introduction of anti-programmed cell death protein-1 (anti-PD-1) to the clinical management of triple-negative breast cancer (TNBC) represents a breakthrough for a disease whose treatment has long relied on the standards of chemotherapy and surgery. Nevertheless, few TNBC patients achieve a durable remission in response to anti-PD-1, and there is a need to develop strategies to maximize the potential benefit of immune checkpoint inhibition (ICI) for TNBC patients. In the present review, we discuss three conceptual strategies to improve ICI response rates in TNBC patients. The first effort involves improving patient selection. We discuss proposed biomarkers of response and resistance to anti-PD-1, concluding that an optimal biomarker will likely be multifaceted. The second effort involves identifying existing targeted therapies or chemotherapies that may synergize with ICI. In particular, we describe recent efforts to use inhibitors of the PI3K/AKT or RAS/MAPK/ERK pathways in combination with ICI. Third, considering the possibility that targeting the PD-1 axis is not the most promising strategy for TNBC treatment, we describe ongoing efforts to identify novel immunotherapy strategies.
Insights
Improving immunotherapy for triple-negative breast cancer (TNBC) requires better patient selection and combination therapies. Researchers are exploring novel strategies beyond anti-programmed cell death protein-1 (anti-PD-1) to enhance durable remissions.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Triple-negative breast cancer (TNBC) treatment historically relied on chemotherapy and surgery.
- Anti-programmed cell death protein-1 (anti-PD-1) therapy offers a breakthrough but benefits few TNBC patients.
- Durable remission rates in TNBC patients treated with anti-PD-1 remain limited, necessitating improved strategies.
Purpose of the Study:
- To review conceptual strategies for enhancing immune checkpoint inhibition (ICI) response rates in TNBC.
- To explore methods for improving patient selection for anti-PD-1 therapy.
- To identify synergistic targeted therapies and novel immunotherapy approaches for TNBC.
Main Methods:
- Review of current literature on biomarkers for anti-PD-1 response and resistance in TNBC.
- Analysis of existing targeted therapies (e.g., PI3K/AKT, RAS/MAPK/ERK inhibitors) for synergy with ICI.
- Exploration of emerging immunotherapy strategies beyond PD-1 axis inhibition for TNBC.
Main Results:
- Optimal biomarkers for anti-PD-1 response in TNBC are likely multifaceted.
- Combination therapies involving PI3K/AKT or RAS/MAPK/ERK pathway inhibitors show potential synergy with ICI.
- Ongoing research is identifying novel immunotherapy targets for TNBC.
Conclusions:
- Enhancing ICI efficacy in TNBC requires multifaceted approaches.
- Improved patient stratification and combination therapies are crucial for maximizing anti-PD-1 benefits.
- Further investigation into novel immunotherapies is warranted for TNBC treatment.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...